Search Title by author or title

Initial outcomes with customized myopic LASIK, guided by automated ray tracing optimization: a novel technique

Poster Details

First Author: A.Kanellopoulos GREECE

Co Author(s):                        

Abstract Details


To report the initial visual outcomes with a novel automated ray-tracing optimization in customization of excimer ablation in myopic LASIK

Setting: Clinical and Research Eye Institute


In a consecutive case-series 25 patients (50 eyes) treated with myopic femtosecond-laser assisted LASIK with this technique: The novel artificial intelligence platform calculates the ablation profile on model eye parameters defined by interferometry axial length data from each eye: ray tracing refraction, and high order aberrations optimization calculations, based on Wavefront and Scheimpflug tomography measurements, all from a single diagnostic device. Visual function: Acuity, refractive error, keratometry, topography, high order aberrations and contrast sensitivity and repeat final postoperative refraction and aberrations calculation were evaluated, over six months follow-up.


Change from pre- to post-operative: mean refractive error was from -5.49 ± 2.54 diopters (D) (range -8.0 to -0.50 D) to -0.07 ± 0.09 D at 6 months; Refractive astigmatism from -1.07 ± 0.91 diopters (D) (range -3.75 to 0 D) to -0.11 ± 0.04 D, topographic astigmatism from -1.65 ± 0.85 to -0.26 ± 0.11. 65% of eyes gained one line of vision and 38% 2 lines. Pre-to –post high order aberrations average: RMSh changed from 0.25 um to 0.35 um. Contrast sensitivity improved post-operatively as an average.


We report herein early clinical outcomes of novel automated excimer laser customization with ray tracing optimization, for myopic LASIK treatments, employing several independent up-till-now diagnostics and a customized eye model reference for each case. It bears the potential advantage through total eye aberration data and ray tracing refraction calculation to offer improved and more predictable visual outcomes.

Financial Disclosure:


Back to Poster listing